Australian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an initial $1.65 billion (€1.44 billion), combining Telix’s commercial radiopharma business with one of Europe’s largest producers of therapeutic radioisotopes.
Dutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year.
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
Belgian-Dutch immunology company argenx has agreed to acquire Forte Biosciences for $2.2 billion (€1.9 billion), gaining FB102, an early-stage antibody that has already produced efficacy signals in vitiligo and celiac disease.
UK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline.
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.
Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
Paris-based Ipsen has agreed to acquire Swiss biotech Memo Therapeutics AG in a deal worth more than €700m, adding the clinical-stage BK polyomavirus antibody potravitug to its rare-disease pipeline.
Paris-based Ipsen has agreed to acquire US biotech Kartos Therapeutics in a deal worth up to $1.75bn, adding a late-stage blood cancer programme to its growing oncology pipeline.
Thalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Novartis